


## **Overview**

An estimated 200 million people have COPD, of which about 3.2 million die each year, making it the third-leading cause of death worldwide. Tiotropium bromide is a long-acting inhaled anticholinergic agent and one of the first-line maintenance therapies in symptomatic patients with moderate-to-severe COPD.

Developing effective treatments for respiratory disorders requires a CRO partner with the specialized expertise and relevant experience to address the complex challenges involved in such trials. Cliantha Research is full service global CRO with a unique approach to clinical development & is well suited to manage some of the industry's most complex and challenging respiratory clinical trials.

	Molecule	Tiotropium Bromide Inhalation Powder
		Hetropium Bronniae innanation i ostae.
	Indication	Moderate to Severe COPD
	Phase of Study	
		Phase III Clinical Endpoint
	Population	
		Patients diagnosed with moderate to severe COPD
	Patients	
		300 randomized (225 India + 75 US)
	Sites	
		18 (India) + 8 (US)

## **CHALLENGES**



## **Cliantha Advantages:**

Presence of category experienced project managers in India & US lead to:

- > An efficient study startup including regulatory support to drive streamlined approvals sooner than estimated
- Choosing high caliber PIs and sites to participate in the study
- Standardized training during key procedures of study led to high quality outcomes

- > Successful recruitment of the right patient population and retaining patients in the study.
- Regular monitoring to keep PIs and their sites on track and to ensure high quality outcomes to form a discriminative and robust study for our sponsors.

What makes our sponsors choose us among competitors for respiratory clinical trials?



Contact Cliantha for more information about how we can make your patient-based trial successful.

For more information contact:

Ranjit Rajput, GM - Business Development
info@cliantha.com